Literature DB >> 19226630

Extreme sensitivity of botulinum neurotoxin domains towards mild agitation.

Stephen I Toth1, Leonard A Smith, S Ashraf Ahmed.   

Abstract

Botulinum neurotoxins (BoNTs) and their fragments are targets of therapeutic developments and are increasingly used as therapeutic, prophylactic, and research reagents. However, published data on their properties vary widely. In order to gain a better understanding of these variations, we initiated a systematic investigation of the stability parameters of catalytic light chains (Lc) as well as of cell surface binding domains (Hc) of the neurotoxin. When followed by CD spectroscopy, we noticed that the recombinant light chains of serotypes A (LcA), B, D, E, and G rapidly lost their secondary structures by mild stirring. Denaturation of LcA increased with stirring speed and temperature resulting in a catalytically inactive precipitate. Reducing agents or an anaerobic environment were ineffective in the denaturation. Under identical conditions, bovine serum albumin, ovalbumin, carboxypeptidase B, and of thermolysin, a structural and functional analogue of LcA, remained unchanged. Hc domains of serotype A, B, C, E, and F were also denatured by mild stirring. Adding the nonionic detergent Tween-20 to LcA completely prevented the denaturation. We speculate that the BoNT domains undergo surface denaturation due to rapid exposure of hydrophobic residues by mechanical agitation. This study has important implications for handling BoNT proteins used in therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226630     DOI: 10.1002/jps.21676

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion.

Authors:  Ryuichiro Atarashi; Katsuya Satoh; Kazunori Sano; Takayuki Fuse; Naohiro Yamaguchi; Daisuke Ishibashi; Takehiro Matsubara; Takehiro Nakagaki; Hitoki Yamanaka; Susumu Shirabe; Masahito Yamada; Hidehiro Mizusawa; Tetsuyuki Kitamoto; Genevieve Klug; Amelia McGlade; Steven J Collins; Noriyuki Nishida
Journal:  Nat Med       Date:  2011-01-30       Impact factor: 53.440

2.  Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity.

Authors:  Martha Hale; George Oyler; Subramanyam Swaminathan; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

3.  Real-time quaking-induced conversion: a highly sensitive assay for prion detection.

Authors:  Ryuichiro Atarashi; Kazunori Sano; Katsuya Satoh; Noriyuki Nishida
Journal:  Prion       Date:  2011-07-01       Impact factor: 3.931

4.  The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Authors:  Rahman M Mizanur; Verna Frasca; Subramanyam Swaminathan; Sina Bavari; Robert Webb; Leonard A Smith; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

5.  Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery.

Authors:  Philip A Band; Steven Blais; Thomas A Neubert; Timothy J Cardozo; Konstantin Ichtchenko
Journal:  Protein Expr Purif       Date:  2010-01-04       Impact factor: 1.650

6.  Tyrosine phosphorylation of botulinum neurotoxin protease domains.

Authors:  Stephen Toth; Ernst E Brueggmann; George A Oyler; Leonard A Smith; Harry B Hines; S Ashraf Ahmed
Journal:  Front Pharmacol       Date:  2012-06-04       Impact factor: 5.810

7.  Cleavage of SNAP25 and its shorter versions by the protease domain of serotype A botulinum neurotoxin.

Authors:  Rahman M Mizanur; Robert G Stafford; S Ashraf Ahmed
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

Review 8.  Prion Diagnosis: Application of Real-Time Quaking-Induced Conversion.

Authors:  Hae-Eun Kang; Youngwon Mo; Raihah Abd Rahim; Hye-Mi Lee; Chongsuk Ryou
Journal:  Biomed Res Int       Date:  2017-05-17       Impact factor: 3.411

9.  A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus.

Authors:  Gerard E Francisco; Alexander Balbert; Ganesh Bavikatte; Djamel Bensmail; Stefano Carda; Thierry Deltombe; Nathalie Draulans; Steven Escaldi; Raphael Gross; Jorge Jacinto; Nicholas Ketchum; Franco Molteni; Susana Moraleda; Michael W ODell; Rajiv Reebye; Patrik Säterö; Monica Verduzco-Gutierrez; Heather Walker; Jörg Wissel
Journal:  J Rehabil Med       Date:  2021-01-01       Impact factor: 2.912

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.